CRISPR Therapeutics AG

CRSP

Precision medicineBiotech & pharmaceuticals

$57.54vs prev close▼-1.96(-3.29%)

$44.1252W Range$78.48

39% from low

+10.52 (+22.60%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

2 sells

Concentrated sells

1M net buy

-$6.9M

≈ -144K shares

Portfolio Weight

3.18%

1M -0.40%p

Holding ETFs

2 ETFs

ARKG · ARKK

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -5.3% · Market value -19.8% · Weight -0.40%p

Trade Intensity

Minor adjustment

Basis: weight -0.40%p decrease

Trade Log2-day SELL streak

Date	Action	ETF	Shares	Close	Est. total
26.07.29	SELL	ARKK	35,272	$47.64	$1.7M
26.07.28	SELL	ARKK	108,908	$47.55	$5.2M
26.03.13	BUY	ARKG · ARKK	44,923	$48.75	$2.2M
26.03.12	BUY	ARKG · ARKK	112,815	$48.87	$5.5M
26.03.10	BUY	ARKG · ARKK	280,609	$52.80	$14.8M
26.02.20	BUY	ARKG · ARKK	20,830	$53.46	$1.1M
26.02.19	BUY	ARKG · ARKK	28,055	$54.64	$1.5M
26.02.18	BUY	ARKG · ARKK	37,075	$53.52	$2.0M
26.02.17	BUY	ARKG · ARKK	84,663	$53.17	$4.5M
26.02.13	BUY	ARKG · ARKK	5,910	$53.07	$313.6K
26.02.12	BUY	ARKG · ARKK	31,937	$48.93	$1.6M
26.01.29	BUY	ARKG · ARKK	127,184	$53.35	$6.8M
26.01.28	BUY	ARKG · ARKK	118,827	$53.69	$6.4M
25.12.26	BUY	ARKG · ARKK	23,170	$55.08	$1.3M
25.12.24	BUY	ARKG · ARKK	10,353	$56.71	$587.1K

07.29SELL

35,272

ARKKClose$47.64Est. total$1.7M

07.28SELL

108,908

ARKKClose$47.55Est. total$5.2M

03.13BUY

44,923

ARKG · ARKKClose$48.75Est. total$2.2M

03.12BUY

112,815

ARKG · ARKKClose$48.87Est. total$5.5M

03.10BUY

280,609

ARKG · ARKKClose$52.80Est. total$14.8M

02.20BUY

20,830

ARKG · ARKKClose$53.46Est. total$1.1M

02.19BUY

28,055

ARKG · ARKKClose$54.64Est. total$1.5M

02.18BUY

37,075

ARKG · ARKKClose$53.52Est. total$2.0M

02.17BUY

84,663

ARKG · ARKKClose$53.17Est. total$4.5M

02.13BUY

5,910

ARKG · ARKKClose$53.07Est. total$313.6K

02.12BUY

31,937

ARKG · ARKKClose$48.93Est. total$1.6M

01.29BUY

127,184

ARKG · ARKKClose$53.35Est. total$6.8M

01.28BUY

118,827

ARKG · ARKKClose$53.69Est. total$6.4M

12.26BUY

23,170

ARKG · ARKKClose$55.08Est. total$1.3M

12.24BUY

10,353

ARKG · ARKKClose$56.71Est. total$587.1K

1 / 11

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

1 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

7,514,421

Portfolio Weight

3.18%

in ETF 6.43%

Est. Value

$394M

30D Net

-$7M

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$87.56

vs Current ▲ +50.6% upside

Current$58.12

Low ~ High$44.00 ~ $291.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Citigroup

Buy

$88.00

+51.41%

—

Maintain

2026-08-04

HC Wainwright & Co.

Buy

$80.00

+37.65%

—

Maintain

2026-07-08

Citizens

Market Outperform

$80.00

+37.65%

—

Maintain

2026-07-06

Bernstein

Market Perform

$56.00

-3.65%

—

Maintain

2026-05-13

Citigroup

Buy

$82.00

+41.09%

—

Maintain

2026-05-06

1 / 4

Avg Target

$87.56

vs Current ▲ +50.6% upside

Buy

22 analysts

Strong Buy 5Buy 8Hold 9

Low $44.00

Current $58.12

High $291.00

Firm	Position	Target	Upside	Close	Action	Date
Citigroup	Buy	$88.00	+51.41%	—	Maintain	26.08.04
HC Wainwright & Co.	Buy	$80.00	+37.65%	—	Maintain	26.07.08
Citizens	Market Outperform	$80.00	+37.65%	—	Maintain	26.07.06
Bernstein	Market Perform	$56.00	-3.65%	—	Maintain	26.05.13
Citigroup	Buy	$82.00	+41.09%	—	Maintain	26.05.06

1 / 4

Price Information

Previous Close$59.50

Open$59.72

Day Range$58.93 - $62.53

52-Week Range$44.12 - $78.48

1-Year Change9.92%

Trading Volume

Volume2,453,841

Avg Volume (3mo)1,690,288

Valuation

Market Cap5.8B

Book Value$18.07

Shares Outstanding96,692,653

Financials

Revenue (TTM)13.4M

Net Income-451,139,008

EPS$-4.71

EBITDA-513,174,016

Profitability

P/E Ratio-

P/B Ratio3.29

Return on Equity (ROE)-26.10%

Return on Assets (ROA)-14.20%

Profit Margin0.00%

EV/EBITDA-8.13

Beta1.74

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)75.01

Company Overview

CRISPR Therapeutics AG is a gene editing company developing transformative gene-based medicines for serious diseases using its revolutionary CRISPR/Cas9 platform. Their main products include CASGEVY, a gene-edited cell therapy for hemoglobinopathies, and various CAR T cell therapies and in vivo gene editing programs for oncology, cardiovascular disease, and type 1 diabetes. The company is a leader in the field, with strategic partnerships and a portfolio targeting significant unmet medical needs.

P/B

3.29

High valuation

ROE

-26.1%

Persistent loss

Beta

1.74

High volatility

RSI(14)

75.0

Overbought

AI-generated summary. Not investment advice.

CRISPR Therapeutics AG

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks